SCHEMBL1269786

SCHEMBL1269786

CCCNC(=O)c1nc(NS(=O)(=O)c2ccc(Cl)cc2Cl)ccc1Sc1ccc(S(=O)(=O)N2CCCCC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGDR2 Q9Y5Y4 2/20 0.46
▸ PTGDR Q13258 1/20 0.46
▸ PKM P14618 1/20 0.41
▸ MAPT P10636 3/20 0.41
▸ POLB P06746 2/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ TP53 P04637 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ ADRB2 P07550 1/20 0.39
▸ HSP90AA1 P07900 1/20 0.39
▸ XBP1 P17861 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ TLR9 Q9NR96 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1269560 0.90 ALDH1A1 (0.41) PTGDR2PTGDRMAPTPOLBSMN1; SMN2
SCHEMBL1269799 0.89 PTGDR2 (0.40) PTGDR2PTGDRMAPTPOLBSMN1; SMN2
SCHEMBL1269276 0.89 MAPT (0.41) PTGDR2PTGDRMAPTPOLBSMN1; SMN2
SCHEMBL1268503 0.88 PTGDR2 (0.41) PTGDR2PTGDRMAPTPOLBSMN1; SMN2
SCHEMBL1269783 0.88 ALDH1A1 (0.41) PTGDR2PTGDRMAPTPOLBSMN1; SMN2
SCHEMBL1268898 0.88 PTGDR2 (0.40) PTGDR2PTGDRPKMMAPTPOLB
SCHEMBL1268953 0.87 ALDH1A1 (0.45) PTGDR2PTGDRMAPTPOLBSMN1; SMN2
SCHEMBL1268515 0.87 ALDH1A1 (0.41) PTGDR2PTGDRMAPTPOLBTP53
SCHEMBL1268583 0.86 ALDH1A1 (0.39) PTGDR2PTGDRMAPTPOLBSMN1; SMN2
SCHEMBL1269665 0.84 HTT (0.40) MAPTPOLBSMN1; SMN2TP53MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
EP-1786782-B1 BISARYL-SULFONAMIDES AMGEN INC (US) 2010-03-31 — — EP disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
US-20060084802-A1 Bisaryl-sulfonamides AMGEN INC. 2006-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221584-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG PTGDR2 649/4885PTGDR 709/4885PKM 3049/4885
US-20060084802-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG PTGDR2 649/4885PTGDR 709/4885PKM 3049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback